



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	relugolix, estradiol, and norethindrone acetate
Brand name	Myfembree®
Dosage form(s)	40 mg/1 mg/ 0.5 mg
Manufacturer	Pfizer Canada ULC and Sumitomo Pharma Switzerland GmbH
Submission type	New Submission
Indication reviewed	In premenopausal women for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids (UFs).
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews	The Canadian Drug Expert Committee (CDEC) recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDA-AMC website for more details .
Ministry of Health (the Ministry) Review	The Ministry reviewed clinical and pharmacoeconomic combined reports prepared by the CDA-AMC's CRR , including clinical and pharmacoeconomic evidence review material and the recommendations of the CDEC. The Ministry also considered patient input provided to CDEC and a budget impact assessment. The Ministry received one Your Voice patient input questionnaire responses from patients, caregivers, or patient groups, and two responses to clinical questions from a specialist.
Drug Coverage Decision	Limited Coverage benefit. Special Authority drug list - Province of British Columbia
Date	May 6, 2026

Reason(s)	<p>Drug coverage decision is consistent with the CDEC recommendation to reimburse Myfembree for the treatment of HMB from UFs in patients who are premenopausal if certain conditions are met.</p> <ul style="list-style-type: none"> • Evidence from 2 clinical trials demonstrated that Myfembree resulted in more patients experiencing a meaningful reduction in menstrual blood loss after being on treatment for 6 months compared to placebo. • More patients receiving Myfembree had an improvement in anemia, pain, and health-related quality of life (HRQoL) compared to placebo. • Myfembree may meet patients' need for a treatment that improves symptoms (e.g., bleeding and pain) and HRQoL; however, it is unclear if patients on the medication are able to avoid surgery over the long term. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.
-----------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.